13.3 Serologic Quality Assurance

13.3 Serologic Quality Assurance

Quick Answer: ASCP outline IV.D breaks serologic quality assurance into three pillars - blood samples, reagents, and test procedures - and the exam tests each pillar through specific, checkable rules rather than general "be careful" statements: sample age limits, control testing of every reagent lot, daily equipment QC, and structured competency assessment.

Blood Sample Quality Assurance

Accurate testing starts before the specimen ever reaches the bench. Positive patient identification is the single highest-stakes control point in the entire blood bank: samples and request forms must be labeled at the bedside, at the time of collection, with at least two independent patient identifiers, and many facilities require a dedicated blood bank identification band or barcode system precisely because a misidentified sample can cause a fatal ABO-incompatible transfusion without triggering any other error flag.

Sample age is a frequently tested numeric rule: for a patient who has been pregnant or transfused within the preceding three months (or with an unknown transfusion/pregnancy history), AABB Standards require that the pretransfusion (type and screen) sample be no more than 3 days old at the time of transfusion, because a newly forming alloantibody can appear and rise quickly during that window. Facilities may set the requirement even more conservatively as a uniform policy applied to all patients. The blood bank must also evaluate the sample itself before testing: hemolysis can mask true agglutination or mimic a positive result in some methods, lipemia can interfere with optical or automated reading, and clots in an anticoagulated tube (or absence of clot in a plain tube) both invalidate the specimen and require recollection rather than a workaround.

Reagent Quality Assurance

Every reagent used for patient testing must be shown to perform as expected before it is trusted with a real result. This includes:

• Antisera (blood grouping sera, antiglobulin sera) - each new lot number and each new shipment must be tested against known antigen-positive and antigen-negative reagent red cells before being released for patient use, and many labs repeat abbreviated QC on each day of use.
• Reagent red blood cells (screening cells, panel cells, check cells) - vendor-provided antigenic profiles must be confirmed to react as expected with known-reactive antisera before the lot is placed into service, and cells must be discarded at their expiration date or sooner if hemolysis or contamination is observed.
• Coombs (check) control cells - added after every negative antihuman globulin (AHG) test to confirm that AHG reagent was actually added and remained reactive; a negative AHG result is only valid if the check cells subsequently agglutinate. If check cells fail to agglutinate, the most likely cause is inadequate cell washing (residual patient globulin neutralizing the AHG reagent) or reagent failure, and the entire test must be repeated - the original "negative" cannot be reported.
• Storage and expiration monitoring - reagents are stored per manufacturer instructions with documented temperature logs, and expired reagents are never used regardless of apparent performance.

Test Procedure Quality Assurance

Procedural QA covers everything from instrument calibration to staff competency:

• Equipment QC - serologic centrifuges are calibrated for time and speed against a defined agglutination/button-resuspension standard; refrigerators, freezers, incubators, and water baths have documented temperature logs checked at defined intervals, with corrective action triggered by any out-of-range reading.
• Proficiency testing (PT) - accredited laboratories must enroll in an approved PT program (such as CAP surveys) for each regulated analyte. PT samples must be tested by the same personnel, methods, and frequency used for routine patient samples, and a laboratory may never send a PT sample to another facility for testing or otherwise handle it differently than a patient specimen - doing so is considered PT referral, a serious regulatory violation.
• Competency assessment - CLIA requires documented staff competency assessment through multiple methods, not just one, typically including direct observation of testing performance, monitoring of recorded/reported results, review of PT performance, blind testing of previously analyzed samples, and problem-solving/troubleshooting evaluation - performed at defined intervals, commonly semiannually during the first year of testing an analyte and annually thereafter.
• Deviation and discrepancy management - any discrepancy (for example, an ABO forward/reverse mismatch, a historical type mismatch, or an unexpected change in antibody screen result) must be investigated and resolved, with documentation, before results are released for a transfusion decision; results are never released "pending investigation."

Regulatory Framework

Serologic QA operates under overlapping authorities that the exam expects candidates to recognize by name: AABB Standards for Blood Banks and Transfusion Services (accreditation-driven and the most operationally detailed), the Code of Federal Regulations (21 CFR) enforced by the FDA for blood establishments, and CLIA (Clinical Laboratory Improvement Amendments) enforced through CAP or state survey for personnel competency and general laboratory quality. A well-run blood bank quality system satisfies all three simultaneously rather than treating them as separate checklists.

Section Takeaways

• A pretransfusion sample from a patient transfused or pregnant in the last 3 months must be no more than 3 days old.
• Every new reagent lot or shipment is tested against known positive and negative controls before patient use - vendor QC is never a substitute for in-house verification.
• A negative AHG test is invalid unless check (Coombs control) cells subsequently agglutinate.
• CLIA competency assessment requires multiple methods (observation, PT review, blind samples, problem-solving), not a single annual test.